vs
AMREP CORP.（AXR）与FENNEC PHARMACEUTICALS INC.（FENC）财务数据对比。点击上方公司名可切换其他公司
AMREP CORP.的季度营收约是FENNEC PHARMACEUTICALS INC.的1.1倍（$14.6M vs $13.8M），AMREP CORP.净利率更高（21.6% vs -34.7%，领先56.3%），AMREP CORP.同比增速更快（93.8% vs 73.8%），过去两年AMREP CORP.的营收复合增速更高（-13.6% vs -26.3%）
AMREP是一家总部位于美国新泽西州普林斯顿的企业，核心业务涵盖房地产与媒体服务领域。公司前身为美国地产石油公司，于1961年正式成立，在相关行业拥有六十余年的发展运营历史。
Fennec制药是一家生物制药企业，专注于开发和商业化可降低儿童癌症患者治疗相关副作用的特种疗法，核心产品针对化疗引发的耳毒性，主要市场覆盖北美，服务肿瘤诊疗机构及儿童肿瘤患者群体。
AXR vs FENC — 直观对比
营收规模更大
AXR
是对方的1.1倍
$13.8M
营收增速更快
AXR
高出19.9%
73.8%
净利率更高
AXR
高出56.3%
-34.7%
两年增速更快
AXR
近两年复合增速
-26.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.6M | $13.8M |
| 净利润 | $3.1M | $-4.8M |
| 毛利率 | — | — |
| 营业利润率 | 20.6% | -18.5% |
| 净利率 | 21.6% | -34.7% |
| 营收同比 | 93.8% | 73.8% |
| 净利润同比 | 338.9% | -141.1% |
| 每股收益（稀释后） | $0.58 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXRFENC
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | $13.8M | ||
| Q3 25 | $17.9M | $12.5M | ||
| Q2 25 | $11.2M | $9.7M | ||
| Q1 25 | $7.5M | $8.8M | ||
| Q4 24 | $11.9M | $7.9M | ||
| Q3 24 | $19.1M | $7.0M | ||
| Q2 24 | $19.5M | $7.3M |
净利润AXRFENC
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | $-4.8M | ||
| Q3 25 | $4.7M | $-638.0K | ||
| Q2 25 | $3.9M | $-3.2M | ||
| Q1 25 | $717.0K | $-1.2M | ||
| Q4 24 | $4.0M | $-2.0M | ||
| Q3 24 | $4.1M | $-5.7M | ||
| Q2 24 | $4.1M | $-5.6M |
营业利润率AXRFENC
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | -18.5% | ||
| Q3 25 | 34.4% | -1.5% | ||
| Q2 25 | 31.7% | -28.3% | ||
| Q1 25 | 5.7% | -9.2% | ||
| Q4 24 | 26.4% | -11.8% | ||
| Q3 24 | 26.1% | -74.6% | ||
| Q2 24 | 23.9% | -69.4% |
净利率AXRFENC
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | -34.7% | ||
| Q3 25 | 26.3% | -5.1% | ||
| Q2 25 | 34.8% | -32.7% | ||
| Q1 25 | 9.5% | -13.3% | ||
| Q4 24 | 33.9% | -25.0% | ||
| Q3 24 | 21.3% | -82.2% | ||
| Q2 24 | 21.2% | -76.5% |
每股收益（稀释后）AXRFENC
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | $-0.17 | ||
| Q3 25 | $0.87 | $-0.02 | ||
| Q2 25 | $0.73 | $-0.11 | ||
| Q1 25 | $0.13 | $-0.04 | ||
| Q4 24 | $0.75 | $-0.02 | ||
| Q3 24 | $0.76 | $-0.21 | ||
| Q2 24 | $0.77 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.0M | $36.8M |
| 总债务越低越好 | $21.0K | — |
| 股东权益账面价值 | $139.4M | $35.5M |
| 总资产 | $143.9M | $70.6M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资AXRFENC
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | $36.8M | ||
| Q3 25 | $48.9M | $21.9M | ||
| Q2 25 | $39.5M | $18.7M | ||
| Q1 25 | $36.9M | $22.7M | ||
| Q4 24 | $40.1M | $26.6M | ||
| Q3 24 | $40.4M | $40.3M | ||
| Q2 24 | $29.7M | $43.1M |
总债务AXRFENC
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | $19.4M | ||
| Q2 25 | $26.0K | $19.4M | ||
| Q1 25 | $29.0K | $19.4M | ||
| Q4 24 | $32.0K | $19.3M | ||
| Q3 24 | $34.0K | $32.1M | ||
| Q2 24 | $35.0K | $31.8M |
股东权益AXRFENC
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | $35.5M | ||
| Q3 25 | $134.7M | $-4.5M | ||
| Q2 25 | $130.0M | $-7.5M | ||
| Q1 25 | $126.0M | $-5.9M | ||
| Q4 24 | $125.1M | $-5.9M | ||
| Q3 24 | $122.2M | $-5.2M | ||
| Q2 24 | $118.0M | $-1.4M |
总资产AXRFENC
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | $70.6M | ||
| Q3 25 | $140.7M | $49.3M | ||
| Q2 25 | $133.8M | $44.9M | ||
| Q1 25 | $128.9M | $46.4M | ||
| Q4 24 | $129.1M | $44.9M | ||
| Q3 24 | $127.0M | $58.9M | ||
| Q2 24 | $122.8M | $63.2M |
负债/权益比AXRFENC
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.4M | $-6.0M |
| 自由现金流经营现金流 - 资本支出 | $5.4M | — |
| 自由现金流率自由现金流/营收 | 37.0% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $20.2M | — |
8季度趋势，按日历期对齐
经营现金流AXRFENC
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $-6.0M | ||
| Q3 25 | $9.5M | $1.5M | ||
| Q2 25 | $10.2M | $-3.7M | ||
| Q1 25 | $-3.2M | $-4.3M | ||
| Q4 24 | $-182.0K | $-1.5M | ||
| Q3 24 | $10.7M | $-2.2M | ||
| Q2 24 | $10.7M | $-8.4M |
自由现金流AXRFENC
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $9.7M | — | ||
| Q1 25 | $-3.3M | — | ||
| Q4 24 | $-268.0K | — | ||
| Q3 24 | $10.7M | — | ||
| Q2 24 | $10.3M | — |
自由现金流率AXRFENC
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 86.4% | — | ||
| Q1 25 | -43.4% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 52.5% | — |
资本支出强度AXRFENC
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 2.3% | — |
现金转化率AXRFENC
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | — | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | -4.51× | — | ||
| Q4 24 | -0.05× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
